EUVIMEDEUVIMED entdecken
Crossref

Quality by design development of folic acid–engineered berberine nanoliposomes for targeted triple-negative breast cancer therapy

Roshni Singh, Debopriya Dutta, Namrata Gautam, Meenakshi Tanwar, Karishma Niveria, Disha Mittal, Anita Kamra Verma, Surajita Sahu, Monalisa Mishra, Saurabh Mittal iD, Sushama Talegaonkar

Naunyn-Schmiedeberg's Archives of Pharmacology · 18.11.2026

DOI: 10.1007/s00210-026-06037-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 18.11.2026. Verfasst von Roshni Singh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India. Die Arbeit nennt 77 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) remains one of the most challenging breast cancer subtypes due to the lack of actionable molecular targets and the systemic toxicity associated with standard chemotherapy. Berberine chloride (BBR), a plant-derived isoquinoline alkaloid, exhibits promising anticancer activity; however, its poor solubility and limited bioavailability restrict therapeutic utility. Therefore, liposomal encapsulation was explored to improve BBR delivery, while folic acid functionalization was introduced to enhance preferential interaction with folate receptor-expressing TNBC cells. In this study, folic acid–decorated nanoliposomes were developed to enhance the targeted delivery of BBR to TNBC cells. BBR-loaded liposomes and folic acid–functionalized liposomes were prepared using the solvent injection method and optimized through a Quality-by-Design (QbD) framework. The optimized folate-modified formulation showed a mean particle size of 168.3 nm with an entrapment efficiency of 41.8%, while non-targeted liposomes exhibited a smaller size (95.6 nm) and slightly higher entrapment loading (47.5%). Both systems provided sustained drug release over 72 h, with folate-decorated liposomes demonstrating a more controlled release pattern. Cytotoxicity studies in MDA-MB-231 cells following 24 h of treatment revealed significantly enhanced antiproliferative activity of folate-functionalized nanoliposomes (IC_50 = 24.72 μM) compared to non-targeted liposomes and free BBR. Increased intracellular reactive oxygen species generation following folate-mediated delivery suggested oxidative stress–associated cytotoxicity. Importantly, preliminary safety evaluation using Drosophila melanogaster confirmed the biocompatibility of the liposomal formulations. Overall, folic acid–decorated nanoliposomes substantially improve the therapeutic efficacy of berberine and offer a rational nanocarrier approach for TNBC management.

Schlagwörter

Stichwörter der Autor:innen

BerberineFolate receptor targetingOxidative stressTargeted drug deliveryTriple-negative breast cancer

Autor:innen und Institutionen

  • Department of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India.
  • AKC-Polymer Technology and Applied Research Centre, Sector-155, Noida, U.P., India.
  • Nanobiotech Lab, Kirori Mal College, University of Delhi, Delhi, India.
  • Department of Life Sciences, School of Biosciences and Technology, Galgotias University, Greater Noida, U.P, India.
  • Fellow, Delhi School of Public Health, Institution of Eminence, University of Delhi, Dehi, 110007, India.
  • Neural Development Biology Lab, Department of Life Science, NIT Rourkela, Rourkela, Odisha, India.

ORCID-Profile: Saurabh Mittal

Zitieren

APA

Singh, R., Dutta, D., Gautam, N., Tanwar, M., Niveria, K., Mittal, D., Verma, A. K., Sahu, S., Mishra, M., Mittal, S., & Talegaonkar, S. (2026). Quality by design development of folic acid–engineered berberine nanoliposomes for targeted triple-negative breast cancer therapy. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-06037-7

Vancouver

Singh R, Dutta D, Gautam N, Tanwar M, Niveria K, Mittal D, et al. Quality by design development of folic acid–engineered berberine nanoliposomes for targeted triple-negative breast cancer therapy. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-06037-7

BibTeX
@article{Singh2026,
  author = {Singh, Roshni and Dutta, Debopriya and Gautam, Namrata and Tanwar, Meenakshi and Niveria, Karishma and Mittal, Disha and Verma, Anita Kamra and Sahu, Surajita and Mishra, Monalisa and Mittal, Saurabh and Talegaonkar, Sushama},
  title = {Quality by design development of folic acid–engineered berberine nanoliposomes for targeted triple-negative breast cancer therapy},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-06037-7}
}
Kostenlos starten →